News for DBTX Stock

Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy Summit Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting Decibel Therapeutics Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTO Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Update Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTO Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO Decibel Therapeutics to Participate in Upcoming Investor Conferences Decibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting Decibel Therapeutics to Participate in Upcoming Investor Conferences Decibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update Decibel Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference Decibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate DB-OTO and Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression Across Gene Therapy Pipeline Decibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) Meeting Decibel Therapeutics to Present at the H.C. Wainwright BioConnect Conference Decibel Therapeutics Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors; Christine Poon Steps Down from Board Decibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover and Develop Gene Therapies for Hearing Loss Decibel Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update Decibel Therapeutics to Present at the Barclays Gene Editing & Gene Therapy Summit Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit Decibel Therapeutics Announces Publication of Foundational Study of Noise-related Inner Ear Damage Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss Decibel Therapeutics to Present at Upcoming Investor Conferences Decibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate Secretary Decibel Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update Decibel Therapeutics Appoints Dr. William H. Carson as Chairman of the Board of Directors Decibel Therapeutics Expands World-Class Scientific Advisory Board Decibel Therapeutics to Present at the UBS Global Healthcare Virtual Conference Decibel Therapeutics Reports First Quarter 2021 Financial Results and Corporate Update Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy 24th Annual Meeting Decibel Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference Decibel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update Decibel Therapeutics Added to Russell 2000 Index Decibel Therapeutics to Present at the Barclays Global Healthcare Conference Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference Decibel Therapeutics Announces Pricing of Initial Public Offering